[Yimusake Tablet: safe and efficacious for premature ejaculation].

Area of Science:

• Clinical Urology
• Pharmacological Research
• Men's Health

Background:

• Premature ejaculation (PE) is a common male sexual dysfunction impacting quality of life.
• Objective evaluation of treatment efficacy and safety is crucial for PE management.
• Yimusake Tablet is a potential therapeutic agent for PE.

Purpose of the Study:

• To objectively evaluate the efficacy and safety of Yimusake Tablet for treating premature ejaculation (PE).
• To assess the impact of Yimusake Tablet on intravaginal ejaculation latency time (IELT) and patient satisfaction.
• To investigate the safety profile and adverse events associated with Yimusake Tablet treatment.

Main Methods:

• A multi-centered, open-label, self-compared clinical trial involving 300 diagnosed PE patients.
• 12-week trial duration: 4 weeks placebo, 8 weeks Yimusake Tablet (2 pills/night).
• Primary outcome: change in IELT; secondary outcomes: patient satisfaction, safety, and erectile function (IIEF-5).

Main Results:

• Mean IELT increased significantly from 62.5s at baseline to 222.2s after 8 weeks of Yimusake Tablet.
• Patient satisfaction significantly improved; mild to moderate erectile dysfunction showed improvement in IIEF-5 scores.
• Adverse events were mild (constipation, dry mouth, etc.) and resolved without treatment discontinuation.

Conclusions:

• Yimusake Tablet is a safe and effective medication for treating premature ejaculation (PE).
• The treatment offers significant improvements in ejaculatory latency and patient-reported outcomes.
• The favorable safety profile supports its clinical utility in managing PE.